The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Elisabeth I. Heath

Division of Hematology/Oncology

Barbara Ann Karmanos Cancer Institute

Wayne State University

4100 John R

USA

[email]@karmanos.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, 4100 John R, USA. 2011 - 2013
  • Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA. 2006 - 2011
  • Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, USA. 2005 - 2010

References

  1. A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors. Heath, E.I., Infante, J., Lewis, L.D., Luu, T., Stephenson, J., Tan, A.R., Kasubhai, S., LoRusso, P., Ma, B., Suttle, A.B., Kleha, J.F., Ball, H.A., Dar, M.M. Cancer Chemother. Pharmacol. (2013) [Pubmed]
  2. A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Heath, E.I., Forman, K., Malburg, L., Gainer, S., Suttle, A.B., Adams, L., Ball, H., Lorusso, P. Invest. New. Drugs (2011) [Pubmed]
  3. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Heath, E.I., Blumenschein, G.R., Cohen, R.B., Lorusso, P.M., Loconte, N.K., Kim, S.T., Ruiz-Garcia, A., Chao, R.C., Wilding, G. Cancer Chemother. Pharmacol. (2011) [Pubmed]
  4. A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Heath, E.I., Lorusso, P., Ramalingam, S.S., Awada, A., Egorin, M.J., Besse-Hamer, T., Cardoso, F., Valdivieso, M., Has, T., Alland, L., Zhou, X., Belani, C.P. Invest. New. Drugs (2011) [Pubmed]
  5. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Heath, E.I., Chiorean, E.G., Sweeney, C.J., Hodge, J.P., Lager, J.J., Forman, K., Malburg, L., Arumugham, T., Dar, M.M., Suttle, A.B., Gainer, S.D., LoRusso, P. Clin. Pharmacol. Ther. (2010) [Pubmed]
  6. Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience. Heath, E.I., LoRusso, P.M., Ivy, S.P., Rubinstein, L., Christian, M.C., Heilbrun, L.K. J. Biopharm. Stat (2009) [Pubmed]
  7. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Heath, E.I., Hillman, D.W., Vaishampayan, U., Sheng, S., Sarkar, F., Harper, F., Gaskins, M., Pitot, H.C., Tan, W., Ivy, S.P., Pili, R., Carducci, M.A., Erlichman, C., Liu, G. Clin. Cancer Res. (2008) [Pubmed]
  8. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Heath, E.I., Bible, K., Martell, R.E., Adelman, D.C., Lorusso, P.M. Invest. New. Drugs (2008) [Pubmed]
  9. The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. Heath, E.I., Kattan, M.W., Powell, I.J., Sakr, W., Brand, T.C., Rybicki, B.A., Thompson, I.M., Aronson, W.J., Terris, M.K., Kane, C.J., Presti, J.C., Amling, C.L., Freedland, S.J. Urology (2008) [Pubmed]
  10. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. Heath, E.I., Canto, M.I., Piantadosi, S., Montgomery, E., Weinstein, W.M., Herman, J.G., Dannenberg, A.J., Yang, V.W., Shar, A.O., Hawk, E., Forastiere, A.A. J. Natl. Cancer Inst. (2007) [Pubmed]
  11. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Heath, E.I., Burtness, B.A., Kleinberg, L., Salem, R.R., Yang, S.C., Heitmiller, R.F., Canto, M.I., Knisely, J.P., Topazian, M., Montgomery, E., Tsottles, N., Pithavala, Y., Rohmiller, B., Collier, M., Forastiere, A.A. Invest. New. Drugs (2006) [Pubmed]
  12. New targets in the management of prostate cancer. Heath, E.I., Carducci, M.A. Hematol. Oncol. Clin. North Am. (2006) [Pubmed]
  13. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Heath, E.I., Gaskins, M., Pitot, H.C., Pili, R., Tan, W., Marschke, R., Liu, G., Hillman, D., Sarkar, F., Sheng, S., Erlichman, C., Ivy, P. Clin. Prostate. Cancer (2005) [Pubmed]
 
WikiGenes - Universities